| Institution: | 1. AstraZeneca, Gaithersburg, Maryland;2. Process Development, Century Therapeutics, Philadelphia, Pennsylvania;3. Boehringer Ingelheim, Fremont, California;4. ProUnlimited supporting Boehringer Ingelheim Fremont Inc., Fremont, California;5. Roche Diagnostics GmbH, Penzberg, Germany;6. Genentech Inc., South San Francisco, California;7. Institute of Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, Maryland;8. Pall Life Sciences, Portsmouth, UK
Department of Biology and Biochemistry, University of Houston, Houston, Texas;9. Novartis, Basel, Switzerland;10. Downstream Process Development, GlaxoSmithKline, King of Prussia, Pennsylvania;11. Protein Design and Informatics, GlaxoSmithKline, Collegeville, Pennsylvania;12. Department of Biology and Biochemistry, University of Houston, Houston, Texas;13. BioProcess Development, MRL, Merck & Co., Inc., Kenilworth, New Jersey;14. Purification Process Development, Sanofi-aventis, Cambridge, Massachusetts;15. Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York;16. Department of Chemical and Biological Engineering, The University of British Columbia, Vancouver, British Columbia, Canada |
